Literature DB >> 7478601

The physical map of the human RET proto-oncogene.

B Pasini1, R M Hofstra, L Yin, R Bocciardi, G Santamaria, P M Grootscholten, I Ceccherini, G Patrone, M Priolo, C H Buys.   

Abstract

The RET proto-oncogene, a transmembrane tyrosine kinase receptor, is involved in the development of at least five different disease phenotypes. RET is activated through somatic rearrangements in a number of cases of papillary thyroid carcinoma while germ-line point mutations are associated with three inherited cancer syndromes MEN 2A, MEN 2B and FMTC. Moreover, point mutations or heterozygous deletions of RET are found in the dominant form of Hirschsprung disease or congenital colonic aganglionosis. We cloned the entire RET genomic sequence in a contig of cosmids encompassing 150 kb, from the CA repeat sTCL-2 to the region upstream the RET promoter, and established the position of the 20 exons of the RET gene with respect to a detailed restriction map based on eight endonucleases. A new highly polymorphic CA repeat sequence was identified within intron 5 of RET (RET-INT5). Finally the orientation of RET on chromosome 10q11.2 made it possible to orientate three other genes rearranged with RET in papillary thyroid carcinomas, namely H4/D10S170 on 10q21, R1 alpha on 17q23 and RFG2/Ele1 on 10q11.2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478601

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

Review 1.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 2.  RET TKI: potential role in thyroid cancers.

Authors:  Alessandro Antonelli; Poupak Fallahi; Silvia Martina Ferrari; Caterina Mancusi; Michele Colaci; Libero Santarpia; Clodoveo Ferri
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

3.  Mutation of RET proto-oncogene in Hirschsprung's disease and intestinal neuronal dysplasia.

Authors:  Jin-Fa Tou; Min-Ju Li; Tao Guan; Ji-Cheng Li; Xiong-Kai Zhu; Zhi-Gang Feng
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 4.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Authors:  Alexander Drilon; Zishuo I Hu; Gillianne G Y Lai; Daniel S W Tan
Journal:  Nat Rev Clin Oncol       Date:  2017-11-14       Impact factor: 66.675

Review 5.  Thyroid Cancer: Role of RET and Beyond.

Authors:  Francesca Carlomagno
Journal:  Eur Thyroid J       Date:  2012-03-28

6.  Studies of RET gene expression and acetylcholinesterase activity in a series of sporadic Hirschsprung's disease.

Authors:  Maria Cecília M Coelho; Uenis Tannuri; Israel Benditt; Maria Merces Santos
Journal:  Pediatr Surg Int       Date:  2008-07-30       Impact factor: 1.827

Review 7.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

8.  Induction of RET dependent and independent pro-inflammatory programs in human peripheral blood mononuclear cells from Hirschsprung patients.

Authors:  Marta Rusmini; Paola Griseri; Francesca Lantieri; Ivana Matera; Kelly L Hudspeth; Alessandra Roberto; Joanna Mikulak; Stefano Avanzini; Valentina Rossi; Girolamo Mattioli; Vincenzo Jasonni; Roberto Ravazzolo; William J Pavan; Alessio Pini-Prato; Isabella Ceccherini; Domenico Mavilio
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

Review 9.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

Review 10.  Stem cell-based therapy for hirschsprung disease, do we have the guts to treat?

Authors:  Ali Fouad Alhawaj
Journal:  Gene Ther       Date:  2021-06-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.